Sugi Predict

Sugi Predict / Compounds / SCHEMBL4220262

SCHEMBL4220262

SCHEMBL4220262

CCOC(=O)c1ccc(NC(=O)N2CCn3c(c(C(N)=O)c(Cl)c3-c3cccnc3)C2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ MAPK1 P28482 4/20 0.46
▸ ALDH1A1 P00352 4/20 0.46
▸ MAPT P10636 4/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ HTT P42858 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ RAB9A P51151 3/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ NPC1 O15118 2/20 0.45
▸ POLB P06746 2/20 0.43
▸ CSNK1E P49674 2/20 0.43
▸ GAA P10253 2/20 0.43
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4037798 0.90 MAPK1 (0.55) KMT2AMEN1MAPK1ALDH1A1MAPT
SCHEMBL6673137 0.88 CSNK1E (0.47) CSNK1ECSNK1D
SCHEMBL14368461 0.85 CSNK1E (0.53) CSNK1ECSNK1D
SCHEMBL14368460 0.84 CSNK1E (0.52) CSNK1ECSNK1D
SCHEMBL14393983 0.84 CSNK1E (0.46) CSNK1ECSNK1D
SCHEMBL14393987 0.83 TRPV1 (0.52) CSNK1ECSNK1D
SCHEMBL4038686 0.82 MAPT (0.48) KMT2AMEN1MAPK1MAPTCSNK1E
SCHEMBL14368436 0.81 CSNK1E (0.56) CSNK1ECSNK1D
SCHEMBL4213339 0.80 MEN1 (0.53) KMT2AMEN1MAPK1ALDH1A1MAPT
SCHEMBL14368463 0.80 CSNK1E (0.62) CSNK1ECSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090281301-A1 Manufacturing Process of 2' ,2' - Difluoronucleoside and Intermediate DONG-A-PHARM.CO LTD (KR) 2009-11-12 — — US disclosed
EP-1436291-B1 INDOLIZINES AS KINASE PROTEIN INHIBITORS AVENTIS PHARMA SA (FR) 2009-01-14 — — EP disclosed
EP-1436291-B1 INDOLIZINES AS KINASE PROTEIN INHIBITORS AVENTIS PHARMA SA (FR) 2009-01-14 — — EP disclosed
US-20070238734-A1 JNK INHIBITORS SANOLI-AVENTIS (FR) 2007-10-11 — — US disclosed
US-20070238734-A1 JNK INHIBITORS SANOLI-AVENTIS (FR) 2007-10-11 — — US disclosed
US-20070238734-A1 JNK INHIBITORS SANOLI-AVENTIS (FR) 2007-10-11 — — US disclosed
US-7148215-B2 Prodrugs as antihistamines or anticarcinogenic agents AVENTIS PHARMA S.A. (FR) 2006-12-12 — — US disclosed
US-20050009831-A1 Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents AVENTIS PHARMA S.A, (FR) 2005-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238734-A1 JNK INHIBITORS MAP3K7, MAPKAPK2, MAPK7 KMT2A 2686/4885MEN1 3865/4885MAPK1 5/4885
US-20050009831-A1 Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents CNKSR1, ROS1, NRAS KMT2A 1910/4885MEN1 3716/4885MAPK1 16/4885
US-20090281301-A1 Manufacturing Process of 2' ,2' - Difluoronucleoside and Intermediate DERA, ALDOA, ENY2 KMT2A 3478/4885MEN1 4760/4885MAPK1 4693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.